Fresenius Medical Care Corporation (FMS)
Official siteHEALTHCARE • MEDICAL CARE FACILITIES • NYSE
Market Cap: $11.43B
Last updated: Nov 17, 2026 at 11:06 AM ET
Fresenius Medical Care Corporation (FMS) Financials: Revenue, Profit and Cash Flow
Fresenius Medical Care reported revenue of EUR 19.63B for the fiscal year ended Dec 31, 2025, up 1.5% from the year before. That year, net income was EUR 978.37M with a net margin of 5.0%, operating cash flow was EUR 2.58B and free cash flow was EUR 1.70B. The quarter ended Sep 30, 2026 had revenue of EUR 4.94B and net income of EUR 159.78M.
Revenue and Margins
The operating margin was 9.3% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from EUR 17.03B, a compound annual rate of 1.6%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | 19.63B | +1.5% | 25.6% | 9.3% | 5.0% |
| Dec 2024 | 19.34B | -0.6% | 24.6% | 7.6% | 2.8% |
| Dec 2023 | 19.45B | +0.3% | 25.3% | 7.0% | 2.6% |
| Dec 2022 | 19.40B | +10.1% | 25.2% | 7.8% | 3.5% |
| Dec 2021 | 17.62B | -1.3% | 27.1% | 10.5% | 5.5% |
| Dec 2020 | 17.86B | +2.2% | 31.0% | 12.9% | 6.5% |
| Dec 2019 | 17.48B | +5.6% | 30.9% | 13.0% | 6.9% |
| Dec 2018 | 16.55B | -7.0% | 31.2% | 18.4% | 12.0% |
| Dec 2017 | 17.78B | +4.4% | 33.8% | 13.3% | 7.2% |
| Dec 2016 | 17.03B | N/A | 32.3% | 14.7% | 6.9% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 81.9% from the year before. In the quarter ended Sep 2026, net income fell 41.9% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 19.63B | 19.34B | 19.45B | 19.40B | 17.62B | 17.86B | 17.48B | 16.55B | 17.78B | 17.03B |
| Cost of revenue | 14.60B | 14.58B | 14.53B | 14.50B | 12.85B | 12.32B | 12.08B | 11.39B | 11.78B | 11.53B |
| Gross profit | 5.03B | 4.76B | 4.93B | 4.89B | 4.77B | 5.54B | 5.40B | 5.16B | 6.00B | 5.50B |
| Research and development | 157.97M | 183.49M | 231.97M | 228.62M | 220.78M | 193.77M | 168.03M | 134.00M | 131.00M | 154.04M |
| Operating income | 1.83B | 1.47B | 1.37B | 1.51B | 1.85B | 2.30B | 2.27B | 3.04B | 2.36B | 2.51B |
| Net income | 978.37M | 537.91M | 499.00M | 673.40M | 969.31M | 1.16B | 1.20B | 1.98B | 1.28B | 1.18B |
| EBITDA | 3.40B | 3.21B | 3.21B | 3.42B | 3.55B | 4.13B | 3.92B | N/A | 3.15B | 3.17B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.94B | 4.86B | 4.61B | 5.07B | 4.88B | 4.79B | 4.88B | 5.08B | 4.76B | 4.77B | 4.72B | 4.99B |
| Gross profit | 1.28B | 1.31B | 1.18B | 1.39B | 1.24B | 1.21B | 1.18B | 1.27B | 1.15B | 1.17B | 1.17B | 1.35B |
| Operating income | 374.64M | 465.86M | 375.56M | 548.98M | 501.72M | 394.40M | 381.73M | 398.93M | 462.70M | 425.00M | 246.01M | 427.65M |
| Net income | 159.78M | 218.38M | 117.53M | 327.08M | 274.80M | 225.27M | 151.22M | 66.90M | 213.03M | 187.00M | 70.96M | 187.93M |
Balance Sheet
As of Dec 2025, total debt of EUR 7.89B exceeded cash and equivalents by 6.29B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 31.00B | 33.57B | 33.93B | 35.75B | 34.37B | 31.69B | 32.93B | 26.24B | 24.03B | 25.50B |
| Current assets | 7.90B | 7.92B | 8.70B | 8.20B | 7.97B | 7.28B | 7.17B | 7.85B | 6.37B | 6.88B |
| Cash and equivalents | 1.60B | 1.18B | 1.40B | 1.27B | 1.48B | 1.08B | 1.01B | 2.15B | 978.11M | 708.88M |
| Total liabilities | 16.72B | 17.80B | 19.10B | 20.30B | 20.39B | 19.36B | 19.71B | 13.34B | 13.20B | 14.45B |
| Short-term debt | 2.20B | 1.22B | 1.56B | 2.02B | 2.59B | 1.70B | 3.26B | 2.50B | 1.65B | 1.30B |
| Long-term debt | 5.69B | 6.26B | 6.96B | 7.17B | 6.65B | 6.80B | 6.46B | 5.02B | 5.77B | 6.80B |
| Shareholder equity | 14.28B | 14.58B | 13.62B | 13.99B | 12.70B | 12.33B | 11.96B | 11.76B | 9.82B | 9.98B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 31.45B | 31.29B | 31.47B | 31.00B | 30.89B | 31.29B | 32.74B | 33.57B | 32.51B | 33.90B | 34.34B | 33.93B |
| Total liabilities | 17.69B | 17.76B | 17.26B | 16.72B | 16.98B | 16.96B | 17.23B | 17.80B | 17.72B | 18.71B | 19.20B | 19.10B |
| Cash and equivalents | 1.10B | 1.06B | 1.24B | 1.60B | 1.26B | 1.72B | 1.07B | 1.18B | 1.37B | 1.09B | 1.15B | 1.40B |
| Shareholder equity | 12.79B | 12.56B | 13.24B | 14.28B | 12.95B | 13.27B | 14.37B | 14.58B | 13.62B | 13.93B | 13.91B | 13.62B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 65.9% of operating cash flow. Dividends came to 23.9% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 2.58B | 2.39B | 2.63B | 2.17B | 2.49B | 4.23B | 2.57B | 2.06B | 2.19B | 2.03B |
| Capital expenditures | 879.24M | 699.36M | 684.60M | 1.41B | 1.68B | 2.09B | 2.24B | 2.06B | 1.78B | 1.94B |
| Free cash flow | 1.70B | 1.69B | 1.94B | 756.00M | 806.00M | 2.15B | 329.00M | 2.00M | 407.00M | 93.18M |
| Dividends paid | 405.84M | 349.16M | 328.62M | 395.56M | 392.45M | 351.17M | 354.64M | 324.84M | 293.97M | N/A |
| Investing cash flow | -666.18M | -84.94M | -544.23M | -734.73M | -1.20B | -1.33B | -3.29B | -245.04M | -991.54M | N/A |
| Financing cash flow | -1.38B | -2.57B | -1.86B | -1.62B | -1.02B | -2.66B | -466.63M | -681.74M | -798.63M | N/A |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 797.56M | 860.30M | 226.89M | 974.54M | 741.56M | 774.93M | 162.82M | 831.70M | 984.71M | 442.42M | 127.31M | 719.07M |
| Capital expenditures | 237.97M | 240.40M | 190.07M | 410.42M | 192.21M | 154.38M | 145.76M | 240.69M | 165.35M | 159.42M | 133.90M | 250.28M |
| Free cash flow | 559.59M | 619.90M | 36.82M | 564.11M | 549.35M | 620.55M | 17.06M | 591.01M | 819.36M | 283.01M | -6.59M | 468.79M |
Frequently Asked Questions About FMS
What is Fresenius Medical Care's annual revenue?
Fresenius Medical Care reported revenue of EUR 19.63B for the fiscal year ended Dec 31, 2025.
How fast is Fresenius Medical Care's revenue growing?
Revenue was up 1.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 0.4%.
Is Fresenius Medical Care profitable?
Yes. Fresenius Medical Care reported net income of EUR 978.37M for the fiscal year ended Dec 31, 2025, with a net margin of 5.0%.
How much free cash flow does FMS generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of EUR 2.58B minus capital expenditures of EUR 879.24M produced free cash flow of EUR 1.70B.
How much debt does Fresenius Medical Care have?
The balance sheet dated Dec 31, 2025 reported long-term debt of EUR 5.69B, short-term debt of EUR 2.20B and cash and equivalents of EUR 1.60B.
FMS pages: Overview, Dividends, Financials, Valuation, Competitors